# Zevalin® First Line in Follicular Lymphoma

> **NCT00772655** · PHASE2 · UNKNOWN · sponsor: **Charite University, Berlin, Germany** · enrollment: 60 (estimated)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** 90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00772655
- **Lead sponsor:** Charite University, Berlin, Germany
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-10
- **Primary completion:** 2010-06
- **Final completion:** 2015-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2012-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00772655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00772655, "Zevalin® First Line in Follicular Lymphoma". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00772655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*